Ladademstat, a First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-in-Human Phase I Study of Ladademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia
J. Clin. Oncol 2020 Oct 14;[EPub Ahead of Print], O Salamero, P Montesinos, C Willekens, JA Pérez-Simón, A Pigneux, C Récher, R Popat, C Carpio, C Molinero, C Mascaró, J Vila, MI Arévalo, T Maes, C Buesa, F Bosch, TCP SomervailleFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.